Table 2.
Prognostic factors for PFS, and OS in the univariate analyses. P values in bold font are statistically significant.
| PFS | OS | |||||
|---|---|---|---|---|---|---|
| Time (month) |
95% CI | P value | Time (month) |
95% CI | P value | |
| Sex | 0.15 | 0.52 | ||||
| Female | 10.5 | 5.0–45.8 | 83.3 | 12.6- Not Reached | ||
| Male | 8.3 | 4.3–11.4 | 35.9 | 20.5–56.6 | ||
| Age | < 0.0001 | < 0.0001 | ||||
| ≥ 70 | 3.6 | 1.0–6.1 | 12.8 | 5.7–29.3 | ||
| < 70 | 9.7 | 8.3–36.4 | 83.3 | 30.1- Not Reached | ||
| Enhancement in MRI | 0.03 | 0.002 | ||||
| Yes | 8.3 | 4.7–9.7 | 27.1 | 13.3–39.8 | ||
| No | 37.2 | 5.3–70.9 | Not Reached | 52.3- Not Reached | ||
| KPS | < 0.0001 | < 0.0001 | ||||
| ≥ 80 | 12.5 | 9.2–45.8 | 83.3 | 39.8- Not Reached | ||
| < 80 | 4.7 | 2.8–8.3 | 12.6 | 7.4–27-27.1 | ||
| LN mean | 0.1 | 0.008 | ||||
| ≥ 2.46 | 6.1 | 3.5–9.7 | 26.1 | 10.4–35.9 | ||
| < 2.46 | 11.8 | 7.4–37.2 | Not Reached | 30.1- Not Reached | ||
| LN max | 0.19 | 0.03 | ||||
| ≥ 4.03 | 7.3 | 3.6–10.5 | 29.3 | 12.8–39.8 | ||
| < 4.03 | 11.3 | 5.3–37.2 | Not Reached | 20.5- Not Reached | ||
| Histology | 0.0003 | < 0.0001 | ||||
| DA | 37.2 | 9.5–70.9 | Not Reached | 52.3- Not Reached | ||
| AA | 9.6 | 5.3–11.8 | 27.1 | 11.7- Not Reached | ||
| GBM | 4.7 | 2.9–8.3 | 20.5 | 7.7–30.1 | ||
| IDH status | 0.013 | < 0.0001 | ||||
| Mutant | 45.8 | 9.2–70.9 | Not Reached | Not Reached- Not Reached | ||
| Wild-type | 7.4 | 4.3–9.7 | 26.1 | 12.8–39.8 | ||
| TERT promoter status | 0.019 | 0.054 | ||||
| Mutant | 5.4 | 2.8–9.7 | 13.3 | 7.4–56.6 | ||
| Wild-type | 10.5 | 7.4–37.2 | 52.3 | 26.1- Not Reached | ||
| MGMT | 0.77 | 0.81 | ||||
| Met | 9.7 | 3.0–17.4 | 52.3 | 12.8- Not Reached | ||
| Un-Met | 8.9 | 5.4–11.3 | 27.1 | 18.3- Not Reached | ||
| Adjuvant Therapy | 0.0651 | 0.0002 | ||||
| None | 37.2 | 9.2–70.9 | Not Reached | Not Reached- Not Reached | ||
| CRT | 7.4 | 4.7–9.6 | 26.1 | 12.8–30.0 | ||
| RT Only | 9.2 | 0.9-Not Reached | 32.4 | 12.6- Not Reached | ||
| Chemo Only | 1.6 | 1.0-Not Reached | 7.4 | 5.7- Not Reached | ||
| Treatment | 0.69 | 0.14 | ||||
| Biopsy | 5.3 | 0.9- Not Reached | Not Reached | 12.6- Not Reached | ||
| PR | 7.4 | 3.0–12.5 | 18.3 | 6.2- Not Reached | ||
| STR, GTR | 9.5 | 7.4–12.5 | 48.9 | 29.3- Not Reached | ||
MRI magnetic resonance imaging, KPS Karnofsky performance status, LN lesion-to-contralateral normal brain tissue, DA diffuse astrocytoma, AA anaplastic astrocytoma, GBM glioblastoma, IDH isocitrate dehydrogenase, TERT telomerase reverse transcriptase, MGMT O6-methylguanine-DNA-methyltransferase, Met methylation, CRT chemoradiotherapy, RT radiation therapy, Chemo chemotherapy, PR partial resection, STR subtotal resection, GTR gross total resection, PFS progression-free survival, CI confidence interval, NA not applicable, OS overall survival.